Medical writer: Muriel Cunningham
Pembrolizumab plus chemotherapy failed to prolong overall survival (OS) and progression-free survival (PFS) among patients with PD-L1–positive gastric and gastroesophageal cancers, according to results from the phase III KEYNOTE-062 trial (Abstract LBA4007). Pembrolizumab monotherapy improved OS among patients with high PD-L1 expression but not PFS.
The objective of the KEYNOTE-062 trial (NCT02494583) was to determine the safety and efficacy of first-line treatment with pembrolizumab with and without chemotherapy in patients with gastric or gastroesophageal cancer. This study was conducted in patients with HER2-negative, advanced gastric or gastroesophageal cancer who had a PD-L1 combined positive score (CPS) of 1 or higher. Josep Tabernero, MD, PhD, of Vall d’Hebron University Hospital, Spain, presented the study results.
Patients who met eligibility criteria were randomly selected 1:1:1 to one of the following thre...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Benefits Seen with Apalutamide plus Adt in Metastatic Castration-sensitive Prostate Cancer Next Article
Ado-trastuzumab Emtansine a Potential New Treatment Option for HER2-amplified Advanced Salivary Gland Cancer »
Table of Contents: ASCO 2019
Head and Neck Cancer
Genitourinary Cancer - Prostate Cancer
Developmental Therapeutics - Immunotherapy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.